Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

* Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): * Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy * Strong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting Enrollment * Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027 * Following Review of the Interim Futility Analysis, FDA Granted RMAT and Fast Track Designations for Cema-Cel Underscoring MRD Positivity as an Unmet Need in LBCL

* Phase 1 RESOLUTION Trial in Autoimmune Disease: * Brisk Enrollment Continues Across ALLO-329 Dose Escalation and Lymphodepletion Optimization Cohorts * Clinical Data Update Expected Q4 2026